Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Momentum 2.8/10 is below the 5.0 floor at $95.65 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.3): -0.5; Concentration risk — Counterparty: one specialty pharmacy.
Mirum Pharmaceuticals markets three FDA-approved rare disease medicines: LIVMARLI for cholestatic pruritus in ALGS and PFIC, CTEXLI for CTX (approved Feb 2025), and CHOLBAM for bile acid synthesis disorders. Commercial revenue comes from direct US sales; pipeline includes... Read more
Sell if holding. Momentum 2.8/10 is below the 5.0 floor at $95.65 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.3): -0.5; Concentration risk — Counterparty: one specialty pharmacy. Chart setup: RSI 51 mid-range, Bollinger mid-band. Score 5.8/10, moderate confidence.
Passes 8/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.33, news boost analyst cluster(6), earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent Developments — Mirum Pharmaceuticals, Inc.
Latest news
- MIRM Mirum Pharmaceuticals reports steep Q4 2025 EPS miss, while shares post a small gain in today's trading. - Crowd En — Newser negative
- Mirum Pharmaceuticals, Inc. (MIRM) expected to beat earnings estimates: What to know ahead of Q1 release - MSN — MSN positive
- Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $130.00 at Stifel Nicolaus - MarketBeat — MarketBeat positive
- Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance — Yahoo Finance Singapore positive
- Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo! Financ — Yahoo! Finance Canada positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyone specialty pharmacy10-K Item 1: 'We are commercializing Ctexli and Cholbam in the United States through one specialty pharmacy.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.8/10 is below the 5.0 floor at $95.65 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.3): -0.5; Concentration risk — Counterparty: one specialty pharmacy. Chart setup: RSI 51 mid-range, Bollinger mid-band. Prior stop was $88.95. Score 5.8/10, moderate confidence.
Take-profit target: $127.65 (+33.5% upside). Prior stop was $88.95. Stop-loss: $88.95.
Concentration risk — Counterparty: one specialty pharmacy; Leverage penalty (D/E 1.3): -0.5; Consecutive earnings misses (2).
Mirum Pharmaceuticals, Inc. trades at a P/E of N/A (forward -171.1). TrendMatrix value score: 6.7/10. Verdict: Sell.
17 analysts cover MIRM with a consensus score of 4.3/5. Average price target: $147.
What does Mirum Pharmaceuticals, Inc. do?Mirum Pharmaceuticals markets three FDA-approved rare disease medicines: LIVMARLI for cholestatic pruritus in ALGS and...
Mirum Pharmaceuticals markets three FDA-approved rare disease medicines: LIVMARLI for cholestatic pruritus in ALGS and PFIC, CTEXLI for CTX (approved Feb 2025), and CHOLBAM for bile acid synthesis disorders. Commercial revenue comes from direct US sales; pipeline includes volixibat (PSC/PBC Phase 2b) and brelovitug (HDV Phase 3, acquired via Bluejay in Jan 2026).